Reduction in needle sharing among seattle-area injection drug users across 4 surveys, 1994-2013

American Journal of Public Health

Volumn 106, Issue 2, 2016, Pages 301-307

  Burt, Richard D ^a   Thiede, Hanne ^a  

^a HIV/STD Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ADVERSE EFFECTS; DRUG ABUSE; DRUG USE; FEMALE; HIGH RISK BEHAVIOR; HIV INFECTIONS; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TRENDS; WASHINGTON; YOUNG ADULT;

ADOLESCENT; ADULT; DRUG USERS; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEEDLE SHARING; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; SURVEYS AND QUESTIONNAIRES; WASHINGTON; YOUNG ADULT;

EID: 84955558485     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2015.302959     Document Type: Review

References (39)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2011. Vol. 23. 2013. Available at: http://www.cdc.gov/hiv/library/reports/surveillance/index.html. Accessed November 17, 2015.
2. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: A systematic review. AIDS. 2014;28(10):1509-1519.
3. Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357(9266):1397-1401.
4. Strathdee SA,Galai N, Safaiean M, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: A 10-year perspective. Arch Intern Med. 2001; 161(10):1281-1288.
5. Viral Hepatitis Surveillance United States, 2010. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2012.
6. Vandelli C, Renzo F, Romano L, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gatroenterol. 2004;99(5):855-859.
7. Centers for Disease Control and Prevention. Highimpact HIV prevention: CDC's approach to reducing HIV infections in the United States. 2011. Available at: http://www.cdc.gov/hiv/pdf/policies-NHPC-Booklet. pdf. Accessed November 17, 2015.
8. Valdiserri R, Khalsa J, Dan C, et al. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J PublicHealth. 2014;104(5):816-821.
9. Mitsui T, Iwan K, Kazuo M, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology. 1992;16(5):1109-1114.
10. Des Jarlais C, Perlis T, Friedman SR, et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health. 2000;90(7):1112-1116.
11. Bruneau J, Daniel M, Abrahamowicz M, Zang G, Lamothe F, Vincelette J. Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in Montreal, Canada: A 16-year longitudinal study. Am J Epidemiol. 2011;173(9):1049-1058.
12. Topp L, Day CA, Iversen J, Wand H, Maher L. Fifteen years of HIV surveillance among people who inject drugs: The Australian Needle and Syringe Programsurvey 1995-2009. AIDS. 2011;25(6):835-842.
13. Nelson KE,Galai N, SafaeianM,Strathdee SA, Celentano DD, Vlahov D. Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore,Maryland, 1988-1998.AmJ Epidemiol. 2002;156(7):641-653.
14. Falster K, Kaldor JM, Maher L. Hepatitis C virus acquisition among injecting drug users: A cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004. J Urban Health. 2009;86(1):106-118.
15. Sabbatini A, Carulli B, Villa M, Corrêa Leite ML, Nicolosi A. Recent trends in the HIV epidemic among injecting drug users in Northern Italy, 1993-1999. AIDS. 2001;15:2181-2185.
16. Mehta SH, Galai N, Astemborski J, et al. HIV incidence among injection drug users in Baltimore, Maryland (1988-2004). JAcquir Immune Defic Syndr. 2006; 43(3):368-372.
17. Watters JK. Trends in risk behavior and HIV seroprevalence in heterosexual injection drug users in San Francisco, 1986-1992. J Acquir Immune Defic Syndr. 1994; 7(12):1276-1281.
18. van Ameijden EJC, Coutinho RA. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS. 1998;12(6):625-633.
19. Longshore D, Annon J, AnglinMD.Long-term trends in self-reported HIV risk behavior: injection drug users in Los Angeles, 1987 through 1995. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(1):64-72.
20. Wiebel WW, Jimenez A, Johnson W, et al. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: A four-year prospective study. JAcquir Immune Defic Syndr Hum Retrovirol. 1996;12(3):282-289.
21. Hagan H, Thiede H, WeissNS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91 (1):42-46.
22. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment.AmJ Epidemiol. 2002;155(7):645-653.
23. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149(3):203-213.
24. Thiede H, Romero M, Bordelon K, Hagan H, Murrill CS. Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users. J Urban Health. 2001;78(2):264-278.
25. Heckathorn DD.Respondent-driven sampling: A new approach to the study of hidden populations. Soc Probl. 1997;44(2):174-199.
26. Burt RD, Hagan H, Sabin K, Thiede H. Evaluating respondent-driven sampling in amajor metropolitan area: comparing injection drug users in the 2005 Seattle area national HIV Behavioral Surveillance System survey with participants in the RAVEN and Kiwi studies. Ann Epidemiol. 2010;20(2):159-167.
27. Burt RD, Thiede H. Evaluating consistency in repeat surveys of injection drug users recruited by respondentdriven sampling in the Seattle area: results from the NHBS-IDU1 and NHBS-IDU2 surveys. Ann Epidemiol. 2012;22(5):354-363.
28. Burt RD, Thiede H. Evidence for risk reduction among amphetamine-injecting men who have sex with men: results from the National HIV Behavioral Surveillance surveys in the Seattle area 2008-2012. AIDS Behav. 2014;18(10):1998-2008.
29. Heckathorn DD. Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl. 2002;49(1): 11-34.
30. Friedman SR, Tempalski B, Cooper H, et al. Estimating numbers of injecting drug users inmetropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health. 2004;81(3): 377-400.
31. Goel S, Salganik M. Assessing respondent-driven sampling. Proc Natl Acad Sci U S A. 2010;107(15): 6743-6747.
32. Wejnert C, Pham H, Krishna N, Le B, DiNenno E. Estimating design effect and calculating sample size for respondent-driven sampling studies of injection drug users in the United States. AIDS Behav. 2012;16(4):797-806.
33. Burt RD, Thiede H. Assessing differences in groups randomized by recruitment chain in a respondent-driven sample of Seattle-area injection drug users. Ann Epidemiol. 2014;24(11):861-867.e14.
34. Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: A cohort study. AIDS. 2000;14(5): 605-611.
35. Holtzman D, Barry V, Ouellet LJ, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Prev Med. 2009;49(1):68-73.
36. Kral AH, Lorvick J, Ciccarone D, et al. HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health. 2005;82(1 suppl 1):i43-i50.
37. Kral AH, Lorvick J, Edlin B. Sex-and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr. 2000;24(2):162-167.
38. Des Jarlais DC, Marmor M, Friedmann P, et al. HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic.AmJ Public Health. 2000;90(3):352-359.
39. van Ameijden EJC, van den Hoek JAR, Coutinho RA. The harm reduction approach and risk factors for HIV seroconversion in injecting drug users, Amsterdam. Am J Epidemiol. 1992;136(2):236-243.